Low-density lipoprotein cholesterol (LDL-C) is causal in atherosclerotic cardiovascular disease (ASCVD), still the leading causes of global morbidity and mortality. The 2025 update of the ESC/EAS guidelines for the management of dyslipidemia recommends increasingly stringent, risk-based LDL-C targets. Beyond achieved LDL-C targets, cumulative exposure over time has emerged as a key determinant of ASCVD risk. Accordingly, treatment strategies should evolve from a traditional stepwise approach toward a more proactive, personalized, and target-oriented model; the recognized impact of cumulative LDL-C exposure further reinforces the importance of early, intensive, and sustained lipid lowering therapies (LLT). Despite this awareness and the availability of effective therapies, LDL-C control in clinical practice remains suboptimal. This gap is largely driven by the so called “therapeutic inertia”, involving physician-related factors, patient barriers, and healthcare system constraints; accordingly, fewer than one-third of patients in secondary prevention achieve recommended LDL-C goals. A significant improvement in this situation requires structured treatment algorithms, multidisciplinary care, improved patient education, and integration of digital decision-support tools. A pragmatic framework to improve goal attainment is the estimation of “distance to target”, which enables selection of LLT based on the required percentage reduction from baseline LDL-C levels. This approach facilitates alignment between the expected efficacy of available treatments and individual patient needs. While statins remain first-line therapy, combination regimens are frequently required—particularly in very high-risk patients—including ezetimibe, bempedoic acid, PCSK9 inhibitors, and inclisiran.

LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions / Palloni, M.C., Farella, T., Faggiano, A., Vatri, M., Fattirolli, F., Angelino, E., Ambrosetti, M., Ruscica, M., Corsini, A., Carugo, S., Poli, A., Faggiano, P.. - In: ATHEROSCLEROSIS PLUS. - ISSN 2667-0895. - STAMPA. - 65:(2026), pp. 100574.0-100574.0. [10.1016/j.athplu.2026.100574]

LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions

Vatri, Marco;Fattirolli, Francesco;Poli, Andrea;
2026

Abstract

Low-density lipoprotein cholesterol (LDL-C) is causal in atherosclerotic cardiovascular disease (ASCVD), still the leading causes of global morbidity and mortality. The 2025 update of the ESC/EAS guidelines for the management of dyslipidemia recommends increasingly stringent, risk-based LDL-C targets. Beyond achieved LDL-C targets, cumulative exposure over time has emerged as a key determinant of ASCVD risk. Accordingly, treatment strategies should evolve from a traditional stepwise approach toward a more proactive, personalized, and target-oriented model; the recognized impact of cumulative LDL-C exposure further reinforces the importance of early, intensive, and sustained lipid lowering therapies (LLT). Despite this awareness and the availability of effective therapies, LDL-C control in clinical practice remains suboptimal. This gap is largely driven by the so called “therapeutic inertia”, involving physician-related factors, patient barriers, and healthcare system constraints; accordingly, fewer than one-third of patients in secondary prevention achieve recommended LDL-C goals. A significant improvement in this situation requires structured treatment algorithms, multidisciplinary care, improved patient education, and integration of digital decision-support tools. A pragmatic framework to improve goal attainment is the estimation of “distance to target”, which enables selection of LLT based on the required percentage reduction from baseline LDL-C levels. This approach facilitates alignment between the expected efficacy of available treatments and individual patient needs. While statins remain first-line therapy, combination regimens are frequently required—particularly in very high-risk patients—including ezetimibe, bempedoic acid, PCSK9 inhibitors, and inclisiran.
2026
65
0
0
Goal 3: Good health and well-being
Palloni, Maria Chiara; Farella, Teresa; Faggiano, Andrea; Vatri, Marco; Fattirolli, Francesco; Angelino, Elisabetta; Ambrosetti, Marco; Ruscica, Massi...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1500279
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 2
social impact